Does the media favor ALT or GENB?

In the previous week, Altimmune and Altimmune both had 3 articles in the media. Generate Biomedicines' average media sentiment score of 0.63 beat Altimmune's score of 0.58 indicating that Generate Biomedicines is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Altimmune 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Generate Biomedicines 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer OCUL or ALT?

In the previous week, Ocular Therapeutix and Ocular Therapeutix both had 3 articles in the media. Ocular Therapeutix's average media sentiment score of 0.96 beat Altimmune's score of 0.58 indicating that Ocular Therapeutix is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ocular Therapeutix 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Altimmune 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor ALT or PVLA?

In the previous week, Palvella Therapeutics had 4 more articles in the media than Altimmune. MarketBeat recorded 7 mentions for Palvella Therapeutics and 3 mentions for Altimmune. Palvella Therapeutics' average media sentiment score of 0.96 beat Altimmune's score of 0.58 indicating that Palvella Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Altimmune 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Palvella Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate NNNN or ALT?

Altimmune has a consensus target price of $15.71, indicating a potential upside of 419.48%. Given Altimmune's stronger consensus rating and higher probable upside, analysts clearly believe Altimmune is more favorable than Anbio Biotechnology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Anbio Biotechnology 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Altimmune 2 Sell rating(s) 1 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.55

Which has higher earnings & valuation, NNNN or ALT?

Anbio Biotechnology has higher revenue and earnings than Altimmune. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Anbio Biotechnology $8.65M 228.06 $6.40M N/A N/A Altimmune $40K 14,706.79 -$88.09M -$0.93 N/A

Which has stronger earnings and valuation, ALT or PGEN?

Altimmune has higher earnings, but lower revenue than Precigen. Precigen is trading at a lower price-to-earnings ratio than Altimmune, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Altimmune $40K 14,706.79 -$88.09M -$0.93 N/A Precigen $9.68M 209.93 -$250.64M -$1.18 N/A

Is ALT or PGEN more profitable?

Precigen has a net margin of -646.99% compared to Altimmune's net margin of -214,860.98%. Precigen's return on equity of 717.50% beat Altimmune's return on equity. Company Net Margins Return on Equity Return on Assets Altimmune -214,860.98% -42.57% -35.57% Precigen -646.99% 717.50% 58.48%

Does the media favor ALT or PGEN?

In the previous week, Precigen had 1 more articles in the media than Altimmune. MarketBeat recorded 4 mentions for Precigen and 3 mentions for Altimmune. Precigen's average media sentiment score of 1.69 beat Altimmune's score of 0.58 indicating that Precigen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Altimmune 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Precigen 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Altimmune (ALT) Competitors

$3.02 +0.09 (+2.89%)

Closing price 03:59 PM Eastern

Extended Trading

$3.03 +0.01 (+0.20%)

As of 07:58 PM Eastern

Compare

ALT vs. GENB, OCUL, PVLA, NNNN, and PGEN

Should you buy Altimmune stock or one of its competitors? MarketBeat compares Altimmune with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Altimmune include Generate Biomedicines (GENB), Ocular Therapeutix (OCUL), Palvella Therapeutics (PVLA), Anbio Biotechnology (NNNN), and Precigen (PGEN). These companies are all part of the "pharmaceutical products" industry.

How does Altimmune compare to Generate Biomedicines?

Altimmune (NASDAQ:ALT) and Generate Biomedicines (NASDAQ:GENB) are both pharmaceutical products companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, profitability, valuation, analyst recommendations, media sentiment, risk, institutional ownership and dividends.

In the previous week, Altimmune and Altimmune both had 3 articles in the media. Generate Biomedicines' average media sentiment score of 0.63 beat Altimmune's score of 0.58 indicating that Generate Biomedicines is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Altimmune	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Generate Biomedicines	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Altimmune currently has a consensus target price of $15.71, indicating a potential upside of 419.48%. Generate Biomedicines has a consensus target price of $25.40, indicating a potential upside of 50.56%. Given Altimmune's higher probable upside, equities research analysts plainly believe Altimmune is more favorable than Generate Biomedicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Altimmune	2 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.55
Generate Biomedicines	0 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.86

78.1% of Altimmune shares are held by institutional investors. 1.6% of Altimmune shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Altimmune has higher earnings, but lower revenue than Generate Biomedicines. Generate Biomedicines is trading at a lower price-to-earnings ratio than Altimmune, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Altimmune	$40K	14,706.79	-$88.09M	-$0.93	N/A
Generate Biomedicines	$30.30M	71.38	-$137.17M	-$1.07	N/A

Generate Biomedicines has a net margin of 0.00% compared to Altimmune's net margin of -214,860.98%. Generate Biomedicines' return on equity of 0.00% beat Altimmune's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Altimmune	-214,860.98%	-42.57%	-35.57%
Generate Biomedicines	N/A	N/A	N/A

Summary

Altimmune beats Generate Biomedicines on 8 of the 14 factors compared between the two stocks.

How does Altimmune compare to Ocular Therapeutix?

Ocular Therapeutix (NASDAQ:OCUL) and Altimmune (NASDAQ:ALT) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, media sentiment, profitability, earnings, dividends and risk.

59.2% of Ocular Therapeutix shares are held by institutional investors. Comparatively, 78.1% of Altimmune shares are held by institutional investors. 3.1% of Ocular Therapeutix shares are held by company insiders. Comparatively, 1.6% of Altimmune shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Ocular Therapeutix has a beta of 0.89, meaning that its stock price is 11% less volatile than the broader market. Comparatively, Altimmune has a beta of 0.21, meaning that its stock price is 79% less volatile than the broader market.

Ocular Therapeutix has a net margin of -558.24% compared to Altimmune's net margin of -214,860.98%. Altimmune's return on equity of -42.57% beat Ocular Therapeutix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ocular Therapeutix	-558.24%	-64.28%	-48.15%
Altimmune	-214,860.98%	-42.57%	-35.57%

In the previous week, Ocular Therapeutix and Ocular Therapeutix both had 3 articles in the media. Ocular Therapeutix's average media sentiment score of 0.96 beat Altimmune's score of 0.58 indicating that Ocular Therapeutix is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ocular Therapeutix	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Altimmune	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Ocular Therapeutix currently has a consensus price target of $25.11, suggesting a potential upside of 155.71%. Altimmune has a consensus price target of $15.71, suggesting a potential upside of 419.48%. Given Altimmune's higher probable upside, analysts clearly believe Altimmune is more favorable than Ocular Therapeutix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ocular Therapeutix	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.79
Altimmune	2 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.55

Altimmune has lower revenue, but higher earnings than Ocular Therapeutix. Ocular Therapeutix is trading at a lower price-to-earnings ratio than Altimmune, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ocular Therapeutix	$51.95M	41.39	-$265.94M	-$1.46	N/A
Altimmune	$40K	14,706.79	-$88.09M	-$0.93	N/A

Summary

Altimmune beats Ocular Therapeutix on 8 of the 15 factors compared between the two stocks.

How does Altimmune compare to Palvella Therapeutics?

Altimmune (NASDAQ:ALT) and Palvella Therapeutics (NASDAQ:PVLA) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, risk, institutional ownership, analyst recommendations, earnings, profitability, media sentiment and dividends.

Altimmune has a beta of 0.21, indicating that its stock price is 79% less volatile than the broader market. Comparatively, Palvella Therapeutics has a beta of -0.15, indicating that its stock price is 115% less volatile than the broader market.

Palvella Therapeutics has higher revenue and earnings than Altimmune. Palvella Therapeutics is trading at a lower price-to-earnings ratio than Altimmune, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Altimmune	$40K	14,706.79	-$88.09M	-$0.93	N/A
Palvella Therapeutics	$42.81M	51.19	-$41.72M	-$4.17	N/A

Palvella Therapeutics has a net margin of 0.00% compared to Altimmune's net margin of -214,860.98%. Altimmune's return on equity of -42.57% beat Palvella Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Altimmune	-214,860.98%	-42.57%	-35.57%
Palvella Therapeutics	N/A	-56.87%	-42.50%

Altimmune currently has a consensus target price of $15.71, suggesting a potential upside of 419.48%. Palvella Therapeutics has a consensus target price of $199.53, suggesting a potential upside of 30.57%. Given Altimmune's higher probable upside, research analysts plainly believe Altimmune is more favorable than Palvella Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Altimmune	2 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.55
Palvella Therapeutics	1 Sell rating(s)	0 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	2.94

In the previous week, Palvella Therapeutics had 4 more articles in the media than Altimmune. MarketBeat recorded 7 mentions for Palvella Therapeutics and 3 mentions for Altimmune. Palvella Therapeutics' average media sentiment score of 0.96 beat Altimmune's score of 0.58 indicating that Palvella Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Altimmune	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Palvella Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

78.1% of Altimmune shares are owned by institutional investors. Comparatively, 40.1% of Palvella Therapeutics shares are owned by institutional investors. 1.6% of Altimmune shares are owned by company insiders. Comparatively, 17.2% of Palvella Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Palvella Therapeutics beats Altimmune on 9 of the 17 factors compared between the two stocks.

How does Altimmune compare to Anbio Biotechnology?

Anbio Biotechnology (NASDAQ:NNNN) and Altimmune (NASDAQ:ALT) are both small-cap pharmaceutical products companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, risk, earnings, valuation, analyst recommendations, media sentiment, dividends and institutional ownership.

Anbio Biotechnology has a beta of 4.38, suggesting that its share price is 338% more volatile than the broader market. Comparatively, Altimmune has a beta of 0.21, suggesting that its share price is 79% less volatile than the broader market.

78.1% of Altimmune shares are owned by institutional investors. 1.6% of Altimmune shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

In the previous week, Altimmune had 2 more articles in the media than Anbio Biotechnology. MarketBeat recorded 3 mentions for Altimmune and 1 mentions for Anbio Biotechnology. Anbio Biotechnology's average media sentiment score of 1.87 beat Altimmune's score of 0.58 indicating that Anbio Biotechnology is being referred to more favorably in the media.

Company	Overall Sentiment
Anbio Biotechnology	Very Positive
Altimmune	Positive

Altimmune has a consensus target price of $15.71, indicating a potential upside of 419.48%. Given Altimmune's stronger consensus rating and higher probable upside, analysts clearly believe Altimmune is more favorable than Anbio Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Anbio Biotechnology	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Altimmune	2 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.55

Anbio Biotechnology has a net margin of 0.00% compared to Altimmune's net margin of -214,860.98%. Anbio Biotechnology's return on equity of 0.00% beat Altimmune's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Anbio Biotechnology	N/A	N/A	N/A
Altimmune	-214,860.98%	-42.57%	-35.57%

Anbio Biotechnology has higher revenue and earnings than Altimmune.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Anbio Biotechnology	$8.65M	228.06	$6.40M	N/A	N/A
Altimmune	$40K	14,706.79	-$88.09M	-$0.93	N/A

Summary

Anbio Biotechnology and Altimmune tied by winning 7 of the 14 factors compared between the two stocks.

How does Altimmune compare to Precigen?

Altimmune (NASDAQ:ALT) and Precigen (NASDAQ:PGEN) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, earnings, profitability, dividends, risk, institutional ownership, media sentiment and analyst recommendations.

Precigen has a net margin of -646.99% compared to Altimmune's net margin of -214,860.98%. Precigen's return on equity of 717.50% beat Altimmune's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Altimmune	-214,860.98%	-42.57%	-35.57%
Precigen	-646.99%	717.50%	58.48%

Altimmune has higher earnings, but lower revenue than Precigen. Precigen is trading at a lower price-to-earnings ratio than Altimmune, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Altimmune	$40K	14,706.79	-$88.09M	-$0.93	N/A
Precigen	$9.68M	209.93	-$250.64M	-$1.18	N/A

Altimmune presently has a consensus price target of $15.71, indicating a potential upside of 419.48%. Precigen has a consensus price target of $12.50, indicating a potential upside of 119.30%. Given Altimmune's stronger consensus rating and higher probable upside, analysts clearly believe Altimmune is more favorable than Precigen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Altimmune	2 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.55
Precigen	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

78.1% of Altimmune shares are owned by institutional investors. Comparatively, 33.5% of Precigen shares are owned by institutional investors. 1.6% of Altimmune shares are owned by company insiders. Comparatively, 41.4% of Precigen shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, Precigen had 1 more articles in the media than Altimmune. MarketBeat recorded 4 mentions for Precigen and 3 mentions for Altimmune. Precigen's average media sentiment score of 1.69 beat Altimmune's score of 0.58 indicating that Precigen is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Altimmune	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Precigen	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Altimmune has a beta of 0.21, indicating that its share price is 79% less volatile than the broader market. Comparatively, Precigen has a beta of 1.06, indicating that its share price is 6% more volatile than the broader market.

Summary

Altimmune and Precigen tied by winning 8 of the 16 factors compared between the two stocks.

Get Altimmune News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ALT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ALT vs. The Competition

Export

Metric	Altimmune	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$571.75M	$3.08B	$7.07B	$12.45B
Dividend Yield	N/A	1.86%	2.66%	6.16%
P/E Ratio	-3.25	19.38	27.51	24.87
Price / Sales	14,706.79	350.27	540.69	102.84
Price / Cash	N/A	57.53	48.53	58.59
Price / Book	1.52	4.28	11.01	6.54
Net Income	-$88.09M	$64.45M	$3.57B	$336.70M
7 Day Performance	3.95%	3.18%	2.56%	3.31%
1 Month Performance	-0.82%	3.80%	0.89%	1.68%
1 Year Performance	-21.83%	34.43%	36.84%	31.96%

Altimmune Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ALT Altimmune	2.0495 of 5 stars	$3.03 +2.9%	$15.71 +419.5%	-16.0%	$571.75M	$40K	N/A	50	Analyst Upgrade
GENB Generate Biomedicines	2.5175 of 5 stars	$16.91 +2.7%	$25.40 +50.2%	N/A	$2.17B	$30.30M	N/A	312	News Coverage High Trading Volume
OCUL Ocular Therapeutix	3.0485 of 5 stars	$9.90 +0.6%	$25.11 +153.6%	+7.4%	$2.15B	$51.95M	N/A	230
PVLA Palvella Therapeutics	3.2898 of 5 stars	$154.84 +4.5%	$199.53 +28.9%	+601.3%	$2.13B	$42.81M	N/A	N/A	News Coverage
NNNN Anbio Biotechnology	0.8983 of 5 stars	$13.55 -6.7%	N/A	N/A	$2.09B	$8.65M	N/A	27	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ALT) was last updated on 6/30/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Altimmune (ALT) Competitors

ALT vs. GENB, OCUL, PVLA, NNNN, and PGEN

How does Altimmune compare to Generate Biomedicines?

Summary

How does Altimmune compare to Ocular Therapeutix?

Summary

How does Altimmune compare to Palvella Therapeutics?

Summary

How does Altimmune compare to Anbio Biotechnology?

Summary

How does Altimmune compare to Precigen?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALT vs. The Competition

Altimmune Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Altimmune (ALT) Competitors

ALT vs. GENB, OCUL, PVLA, NNNN, and PGEN

How does Altimmune compare to Generate Biomedicines?

Does the media favor ALT or GENB?

Do analysts recommend ALT or GENB?

Do institutionals & insiders believe in ALT or GENB?

Which has higher valuation and earnings, ALT or GENB?

Is ALT or GENB more profitable?

Summary

How does Altimmune compare to Ocular Therapeutix?

Do institutionals and insiders hold more shares of OCUL or ALT?

Which has more volatility and risk, OCUL or ALT?

Is OCUL or ALT more profitable?

Does the media prefer OCUL or ALT?

Do analysts rate OCUL or ALT?

Which has stronger valuation & earnings, OCUL or ALT?

Summary

How does Altimmune compare to Palvella Therapeutics?

Which has more risk and volatility, ALT or PVLA?

Which has higher earnings & valuation, ALT or PVLA?

Is ALT or PVLA more profitable?

Do analysts recommend ALT or PVLA?

Does the media favor ALT or PVLA?

Do insiders & institutionals believe in ALT or PVLA?

Summary

How does Altimmune compare to Anbio Biotechnology?

Which has more risk and volatility, NNNN or ALT?

Do institutionals & insiders believe in NNNN or ALT?

Does the media refer more to NNNN or ALT?

Do analysts rate NNNN or ALT?

Is NNNN or ALT more profitable?

Which has higher earnings & valuation, NNNN or ALT?

Summary

How does Altimmune compare to Precigen?

Is ALT or PGEN more profitable?

Which has stronger earnings and valuation, ALT or PGEN?

Do analysts rate ALT or PGEN?

Do institutionals and insiders have more ownership in ALT or PGEN?

Does the media favor ALT or PGEN?

Which has more volatility and risk, ALT or PGEN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALT vs. The Competition

Altimmune Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools